Millions of women could soon have greater access to GLP-1 weight loss medications following the global effort to change the name of a hormonal condition that affects 1 in 8 women globally. 

The condition, formerly known as Polycystic Ovarian Syndrome, or PCOS, recently underwent a name change following a years-long international effort, led by the Endocrine Society and women’s health researchers worldwide, to update how clinicians care for women struggling with the disease.